collection
MENU ▼
Read by QxMD icon Read
search

Cholesterol

shared collection
29 papers 0 to 25 followers Interested in managing lipid disorders? Check it out-
By Michael Kelly Assistant Professor
https://www.readbyqxmd.com/read/29217412/glucagon-like-peptide-1-receptor-agonists-reduced-the-low-density-lipoprotein-cholesterol-in-japanese-patients-with-type-ii-diabetes-mellitus-treated-with-statins
#1
Yukiko Hasegawa, Mika Hori, Tomoko Nakagami, Mariko Harada-Shiba, Yasuko Uchigata
BACKGROUND: Patients with type II diabetes mellitus (T2DM) often have hypercholesterolemia, and their serum low-density lipoprotein cholesterol (LDL-C) levels are not always well-controlled even by statin treatment. The glucose-lowering glucagon-like peptide-1 receptor agonists (GLP-1RAs) are reported to change the lipid profiles in T2DM patients, but their effects have been unclear. OBJECTIVE: We examined whether GLP-1RAs affect serum cholesterol levels in T2DM patients with/without statin treatment...
November 21, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29129666/effect-of-soy-isoflavone-supplementation-on-plasma-lipoprotein-a-concentrations-a-meta-analysis
#2
REVIEW
Luis E Simental-Mendía, Antonio M Gotto, Stephen L Atkin, Maciej Banach, Matteo Pirro, Amirhossein Sahebkar
BACKGROUND: Soy supplementation has been shown to reduce total and low-density lipoprotein cholesterol, while increasing high-density lipoprotein cholesterol. However, contradictory effects of soy isoflavone supplementation on lipoprotein(a) [Lp(a)] have been reported suggesting the need for a meta-analysis to be undertaken. OBJECTIVE: The aim of the study was to investigate the impact of supplementation with soy isoflavones on plasma Lp(a) levels through a systematic review and meta-analysis of eligible randomized placebo-controlled trials...
October 17, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29128242/early-changes-of-blood-lipid-levels-during-psychotropic-drug-treatment-as-predictors-of-long-term-lipid-changes-and-of-new-onset-dyslipidemia
#3
Aurélie Delacrétaz, Frederik Vandenberghe, Mehdi Gholam-Rezaee, Nuria Saigi Morgui, Anaïs Glatard, Jacques Thonney, Alessandra Solida-Tozzi, Stéphane Kolly, Sylfa Fassassi Gallo, Philipp Baumann, Sylvie Berney, Sandrine Valloton Zulauff, Jean-Michel Aubry, Roland Hasler, Karsten Ebbing, Armin von Gunten, Philippe Conus, Chin B Eap
BACKGROUND: Cardiovascular diseases and dyslipidemia represent a major health issue in psychiatry. Many psychotropic drugs can induce a rapid and substantial increase of blood lipid levels. OBJECTIVE: This study aimed to determine the potential predictive power of an early change of blood lipid levels during psychotropic treatment on long-term change and on dyslipidemia development. METHODS: Data were obtained from a prospective study including 181 psychiatric patients with metabolic parameters monitored during the first year of treatment and with adherence ascertained...
October 16, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29050979/comparison-of-3-risk-estimators-to-guide-initiation-of-statin-therapy-for-primary-prevention-of-cardiovascular-disease
#4
Sandra Ofori, Sotonye Dodiyi-Manuel, Maclean R Akpa
BACKGROUND: Among high-risk individuals, statins are beneficial for primary prevention of cardiovascular disease (CVD). In Nigeria, currently, there are no CVD prevention guidelines, so the use of CVD risk estimation to guide statin therapy is left to the discretion of the physician. OBJECTIVE: The objective of the study was to compare 3 CVD risk estimation tools in the evaluation of patients presenting to a tertiary hospital in Nigeria. METHODS: Cross-sectional study involving 295 patients with any CVD risk factors but not taking statins...
October 3, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28887086/the-effects-of-cinnamon-supplementation-on-blood-lipid-concentrations-a-systematic-review-and-meta-analysis
#5
Serban M Maierean, Maria-Corina Serban, Amirhossein Sahebkar, Sorin Ursoniu, Alexandru Serban, Peter Penson, Maciej Banach
BACKGROUND: Cinnamon is a rich botanical source of polyphenols, whose positive effects on blood lipid concentrations have been hypothesized, but have not been conclusively studied. OBJECTIVE: The objective of the study was to systematically review and evaluate the effect of administration of cinnamon on blood lipid concentrations. METHODS: We assessed 13 randomized controlled trials with 750 participants investigating the effect of cinnamon supplementation on blood lipid concentrations...
August 12, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28738423/continued-statin-prescriptions-after-adverse-reactions-and-patient-outcomes-a-cohort-study
#6
MULTICENTER STUDY
Huabing Zhang, Jorge Plutzky, Maria Shubina, Alexander Turchin
Background: Many patients discontinue statin treatment, often after having a possible adverse reaction. The risks and benefits of continued statin therapy after an adverse reaction are not known. Objective: To examine the relationship between continuation of statin therapy (any prescription within 12 months after an adverse reaction) and clinical outcomes. Design: Retrospective cohort study. Setting: Primary care practices affiliated with 2 academic medical centers...
August 15, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28754224/residual-atherosclerotic-cardiovascular-disease-risk-in-statin-treated-adults-the-multi-ethnic-study-of-atherosclerosis
#7
Nathan D Wong, Yanglu Zhao, Ruben G W Quek, Roger S Blumenthal, Matthew J Budoff, Mary Cushman, Parveen Garg, Veit Sandfort, Michael Tsai, J Antonio G Lopez
BACKGROUND: Residual atherosclerotic cardiovascular disease (ASCVD) risk in statin-treated US adults without known ASCVD is not well described. OBJECTIVE: To quantitate residual ASCVD risk and its predictors in statin-treated adults. METHODS: We studied 1014 statin-treated adults (53.3% female, mean 66.0 years) free of clinical ASCVD in the Multi-Ethnic Study of Atherosclerosis. We examined ASCVD event rates by National Lipid Association risk groups over 11-year follow-up and the relation of standard risk factors, biomarkers, and subclinical atherosclerosis measures with residual ASCVD event risk...
September 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28673802/regular-activity-breaks-combined-with-physical-activity-improve-postprandial-plasma-triglyceride-nonesterified-fatty-acid-and-insulin-responses-in-healthy-normal-weight-adults-a-randomized-crossover-trial
#8
Ashleigh R Homer, Stephen P Fenemor, Tracy L Perry, Nancy J Rehrer, Claire M Cameron, C Murray Skeaff, Meredith C Peddie
BACKGROUND: Compared with prolonged sitting, regular activity breaks immediately lower postprandial glucose and insulin, but not triglyceride responses. Postprandial triglycerides can be lowered by physical activity but the effect is often delayed by ∼12 to 24 hours. OBJECTIVE: The objective of the study was to determine whether regular activity breaks affect postprandial triglyceride response in a delayed manner similar to physical activity. METHODS: In a randomized crossover trial, 36 adults (body mass index 23...
September 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28669686/pharmacologic-approaches-for-the-management-of-patients-with-moderately-elevated-triglycerides-150-499-mg-dl
#9
REVIEW
Michael S Kelly, Craig Beavers, John D Bucheit, Evan M Sisson, Dave L Dixon
Hypertriglyceridemia, defined as serum triglyceride (TG) levels >150 mg/dL, now affects over one-quarter of the US adult population and is associated with an increased risk of atherosclerotic cardiovascular disease. Available guidelines for managing hypertriglyceridemia vary with respect to TG thresholds and severity of disease. Lifestyle modifications and management of secondary causes (eg, diabetes) remain the first step in managing hypertriglyceridemia, with pharmacotherapy reserved to reduce the risk of pancreatitis and/or further reduce TG levels...
July 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28627235/translating-guidelines-into-practice-interpreting-the-2016-acc-expert-consensus-decision-pathway-on-the-role-of-non-statin-therapies-for-ldl-cholesterol-lowering-in-the-management-of-atherosclerotic-cardiovascular-disease-risk
#10
Laura H Waite, Yvonne L Phan, Sarah A Spinler
OBJECTIVE: In 2016, the American College of Cardiology released a decision pathway, based on expert consensus, to guide use of non-statin agents in the management of atherosclerotic cardiovascular disease risk. The purpose of this article is to assist practitioners, health systems and managed care entities with interpreting this consensus statement in order to simplify implementation of the recommendations into patient care. METHODS: Major themes from the consensus statement are briefly summarized and explained...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28604921/association-of-educational-attainment-with-lifetime-risk-of-cardiovascular-disease-the-atherosclerosis-risk-in-communities-study
#11
Yasuhiko Kubota, Gerardo Heiss, Richard F MacLehose, Nicholas S Roetker, Aaron R Folsom
Importance: Estimates of lifetime risk may help raise awareness of the extent to which educational inequalities are associated with risk of cardiovascular disease (CVD). Objective: To estimate lifetime risks of CVD according to categories of educational attainment. Design, Setting, and Participants: Participants were followed from 1987 through December 31, 2013. All CVD events (coronary heart disease, heart failure, and stroke) were confirmed by physician review and International Classification of Diseases codes...
August 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28532784/update-on-the-use-of-pcsk9-inhibitors-in-adults-recommendations-from-an-expert-panel-of-the-national-lipid-association
#12
Carl E Orringer, Terry A Jacobson, Joseph J Saseen, Alan S Brown, Antonio M Gotto, Joyce L Ross, James A Underberg
An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. Recent studies have demonstrated the efficacy of these agents in reducing low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and have confirmed their excellent safety profile...
July 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28514624/evacetrapib-and-cardiovascular-outcomes-in-high-risk-vascular-disease
#13
RANDOMIZED CONTROLLED TRIAL
A Michael Lincoff, Stephen J Nicholls, Jeffrey S Riesmeyer, Philip J Barter, H Bryan Brewer, Keith A A Fox, C Michael Gibson, Christopher Granger, Venu Menon, Gilles Montalescot, Daniel Rader, Alan R Tall, Ellen McErlean, Kathy Wolski, Giacomo Ruotolo, Burkhard Vangerow, Govinda Weerakkody, Shaun G Goodman, Diego Conde, Darren K McGuire, Jose C Nicolau, Jose L Leiva-Pons, Yves Pesant, Weimin Li, David Kandath, Simon Kouz, Naeem Tahirkheli, Denise Mason, Steven E Nissen
BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease...
May 18, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28465133/jcl-roundtable-future-of-the-lipid-laboratory-choosing-valuable-measures-among-the-lipoproteins-part-1
#14
REVIEW
William Virgil Brown, Yehuda Handelsman, Seth S Martin, Pamela B Morris
The measurement of cholesterol and triglycerides as indicators of metabolic disorders and most particularly of vascular disease risk has been of growing importance to physicians and epidemiologists over the past century. This was refocused on the lipoproteins, the specific packages in blood that carry these lipids, by John Gofman, MD, PhD, and Don Fredrickson, MD, more than 50 years ago. We continue to learn about the metabolism of these large molecular structures and their relationship to arteriosclerosis as new genetic and interventional studies are published...
April 21, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28156151/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease-executive-summarycomplete-appendix-to-guidelines-available-at-http-journals-aace-com
#15
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson, Farhad Zangeneh, Michael A Bush
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Each Recommendation is based on a diligent review of the clinical evidence with transparent incorporation of subjective factors. RESULTS: The Executive Summary of this document contains 87 Recommendations of which 45 are Grade A (51...
April 2, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/27798247/rechallenging-statin-therapy-in-veterans-with-statin-induced-myopathy-post-vitamin-d-replenishment
#16
Jenny H Kang, Quynh-Nhu Nguyen, Juleann Mutka, Quang A Le
BACKGROUND: Statins are the primary class of medications used to lower cholesterol and reduce risks for coronary heart disease. However, statin muscular adverse effects are one of the main reasons for statin nonadherence and a barrier to cardiovascular risk reduction. OBJECTIVES: The primary objective of our study was to examine the effect of replenishing vitamin D on statin-induced myopathy in veteran patients who failed to maintain statin therapy in a pharmacist-run ambulatory care setting...
October 24, 2016: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/27888640/chronotherapy-versus-conventional-statins-therapy-for-the-treatment-of-hyperlipidaemia
#17
REVIEW
Jose Manuel Izquierdo-Palomares, Jesus Maria Fernandez-Tabera, Maria N Plana, Almudena Añino Alba, Pablo Gómez Álvarez, Inmaculada Fernandez-Esteban, Luis Carlos Saiz, Pilar Martin-Carrillo, Óscar Pinar López
BACKGROUND: Elevated levels of total cholesterol and low-density lipoprotein play an important role in the development of atheromas and, therefore, in cardiovascular diseases. Cholesterol biosynthesis follows a circadian rhythm and is principally produced at night (between 12:00 am and 6:00 am). The adjustment of hypolipaemic therapy to biologic rhythms is known as chronotherapy. Chronotherapy is based on the idea that medication can have different effects depending on the hour at which it is taken...
November 26, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27678434/lifestyle-intervention-enhances-high-density-lipoprotein-function-among-patients-with-metabolic-syndrome-only-at-normal-low-density-lipoprotein-cholesterol-plasma-levels
#18
Boris Hansel, Dominique Bonnefont-Rousselot, Alexina Orsoni, Randa Bittar, Philippe Giral, Ronan Roussel, Michel Marre, Kamel Mohammedi, Eric Bruckert, Martin John Chapman, Anatol Kontush
BACKGROUND: Metabolic syndrome (MetS) is associated with altered lipoprotein metabolism and impairment in the functionality of small, dense high-density lipoprotein (HDL) particles secondary to compositional alterations. OBJECTIVE: The objective of this study was to investigate the capacity of a lifestyle program to improve the composition and antioxidative function (AOX) of small dense HDL3c in MetS. METHODS: Patients with MetS (n = 33) not taking lipid-lowering drugs were recruited to follow a 12-week educational program to reduce caloric intake and to increase physical activity...
September 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27678439/efficacy-and-safety-of-gemcabene-as-add-on-to-stable-statin-therapy-in-hypercholesterolemic-patients
#19
RANDOMIZED CONTROLLED TRIAL
Evan Stein, Harold Bays, Michael Koren, Rebecca Bakker-Arkema, Charles Bisgaier
BACKGROUND: Ezetimibe added to statin therapy further reduces LDL-C and clinical atherosclerotic cardiovascular disease compared to statin alone. However, the number of effective and safe oral agents for patients not at LDL-C goal is limited. In prior clinical trials, gemcabene reduced LDL-C and was generally well-tolerated in nearly 900 patients treated for up to 12 weeks. OBJECTIVE: To evaluate the LDL-C lowering and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients...
September 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27567407/2016-esc-eas-guidelines-for-the-management-of-dyslipidaemias
#20
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W M Monique Verschuren, Charalambos Vlachopoulos, David A Wood, Jose Luis Zamorano
No abstract text is available yet for this article.
October 14, 2016: European Heart Journal
label_collection
label_collection
3976
1
2
2016-09-13 00:06:30
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"